[go: up one dir, main page]

SE8601644D0 - Antikroppspreparation riktad mot vissa determinanter i human c3 samt dess anvendning och framstellning - Google Patents

Antikroppspreparation riktad mot vissa determinanter i human c3 samt dess anvendning och framstellning

Info

Publication number
SE8601644D0
SE8601644D0 SE8601644A SE8601644A SE8601644D0 SE 8601644 D0 SE8601644 D0 SE 8601644D0 SE 8601644 A SE8601644 A SE 8601644A SE 8601644 A SE8601644 A SE 8601644A SE 8601644 D0 SE8601644 D0 SE 8601644D0
Authority
SE
Sweden
Prior art keywords
preparation
human
against certain
antibodies
region
Prior art date
Application number
SE8601644A
Other languages
English (en)
Other versions
SE452065B (sv
SE8601644L (sv
Inventor
Ulf R Nilsson
Karl-Erik Svensson
Bo Nilsson
Original Assignee
Ulf R Nilsson
Svensson Karl Erik
Bo Nilsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulf R Nilsson, Svensson Karl Erik, Bo Nilsson filed Critical Ulf R Nilsson
Priority to SE8601644A priority Critical patent/SE452065B/sv
Publication of SE8601644D0 publication Critical patent/SE8601644D0/sv
Priority to AU72868/87A priority patent/AU7286887A/en
Priority to EP19870902799 priority patent/EP0263161A1/en
Priority to PCT/SE1987/000142 priority patent/WO1987006344A1/en
Priority to JP62502520A priority patent/JPS63503089A/ja
Publication of SE8601644L publication Critical patent/SE8601644L/sv
Publication of SE452065B publication Critical patent/SE452065B/sv

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SE8601644A 1986-04-11 1986-04-11 Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning SE452065B (sv)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE8601644A SE452065B (sv) 1986-04-11 1986-04-11 Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
AU72868/87A AU7286887A (en) 1986-04-11 1987-03-19 Antibody preparation directed against neoantigens in human c3 (complement factor 3) and the use and manufacture thereof
EP19870902799 EP0263161A1 (en) 1986-04-11 1987-03-19 Antibody preparation directed against neoantigens in human c3 (complement factor 3) and the use and manufacture thereof
PCT/SE1987/000142 WO1987006344A1 (en) 1986-04-11 1987-03-19 Antibody preparation directed against neoantigens in human c3 (complement factor 3) and the use and manufacture thereof
JP62502520A JPS63503089A (ja) 1986-04-11 1987-03-19 ヒトｃ３中のある抗原決定基に対する抗体調製物及びその使用並びにその生産

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8601644A SE452065B (sv) 1986-04-11 1986-04-11 Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning

Publications (3)

Publication Number Publication Date
SE8601644D0 true SE8601644D0 (sv) 1986-04-11
SE8601644L SE8601644L (sv) 1987-10-12
SE452065B SE452065B (sv) 1987-11-09

Family

ID=20364149

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8601644A SE452065B (sv) 1986-04-11 1986-04-11 Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning

Country Status (5)

Country Link
EP (1) EP0263161A1 (sv)
JP (1) JPS63503089A (sv)
AU (1) AU7286887A (sv)
SE (1) SE452065B (sv)
WO (1) WO1987006344A1 (sv)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
CA2328356A1 (en) * 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
WO2001058483A2 (en) * 2000-02-08 2001-08-16 The University Of Virginia Patent Foundation METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES
US7049397B2 (en) * 2001-04-30 2006-05-23 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons
US6617308B2 (en) * 2001-04-30 2003-09-09 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
US6998243B2 (en) 2001-04-30 2006-02-14 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons
US6593298B2 (en) * 2001-04-30 2003-07-15 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1690 daltons
US6756476B2 (en) * 2001-04-30 2004-06-29 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
US7314717B2 (en) 2001-04-30 2008-01-01 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
US20020160434A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1777 daltons
US20040224423A1 (en) * 2001-04-30 2004-11-11 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 2056 daltons
US6602855B2 (en) * 2001-04-30 2003-08-05 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1449 daltons
US20020160532A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1998 daltons
US7294688B2 (en) * 2001-04-30 2007-11-13 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
US20050255533A1 (en) * 2004-02-10 2005-11-17 Brendan Bioscience, Llc Comprehensive food allergy test
PE20091388A1 (es) * 2007-11-02 2009-09-24 Novartis Ag Moleculas y metodos para modular el componente de complemento
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
JP2013524213A (ja) * 2010-03-31 2013-06-17 アナマー エービー 炎症をもたらす組織分解を検出する方法
EP3095876A1 (en) 2010-11-02 2016-11-23 Kypha, Inc. Point of care lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
GB2117514B (en) * 1982-03-29 1985-08-29 East Anglian Regional Health Polyvalent antiglobulin reagent
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation

Also Published As

Publication number Publication date
WO1987006344A1 (en) 1987-10-22
JPS63503089A (ja) 1988-11-10
SE452065B (sv) 1987-11-09
AU7286887A (en) 1987-11-09
EP0263161A1 (en) 1988-04-13
SE8601644L (sv) 1987-10-12

Similar Documents

Publication Publication Date Title
SE8601644D0 (sv) Antikroppspreparation riktad mot vissa determinanter i human c3 samt dess anvendning och framstellning
FI913891A7 (sv) Ny monoklonal antikropp mot nytt antigen, vilken hänför sig till männi skans tumörer
FI930580A0 (fi) Tri- och tetravalensiska monopecifika antigen bindande proteiner
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
DK0403156T3 (da) Forbedrede monoklonale antistoffer mod den humane alfa/beta-T-cellereceptor samt fremstilling og anvendelse deraf
DE68923027D1 (de) Antigene.
DE69229553D1 (de) Bestimmung der kompatibilität anhand von löslichem hla
FI901791A7 (sv) Bestämning av lymfocyternas reaktivitet i förhållande till specifika antigener i blodet
IT1207589B (it) Composizione di anticorpi monoclonali umani cross-protettivi.
EP0303983A3 (en) Synthetic peptides, antibodies directed against them and their use
DE3884646D1 (de) Humanes Karcinom-assoziertes Antigen und an dieses Antigen bindende Antikörper.
EP0460607A3 (en) Novel monoclonal antibody to novel antigen associated with human tumors
ATE72400T1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
JPS6461499A (en) Monoclonal antibody to human papilloma viruses 16 type e7 protein, and production and use thereof
IT8026986A0 (it) Antigene di prostata umana purificato e procedimento per preparare anticorpi correlati a tale antigene.
NZ222006A (en) Monoclonal antibodies specific to omega-ifn
ATE4282T1 (de) Verfahren zur herstellung von toxoplasmenbereitungen fuer die toxoplasmosediagnose und die so hergestellten bereitungen.
DE3785795D1 (de) Monoklonale anti-menschliche magenkrebs-antikoerper.
ATE137674T1 (de) Von mca 16-88 erkanntes antigen
ATE86261T1 (de) Tumorassoziiertes antigen.
ATE92081T1 (de) Tumorassoziiertes antigen.
DE69111429D1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
KR890009417A (ko) 모노크로날 항체의 제조방법 및 그것의 이용방법
ATE73234T1 (de) Anti-parathyroid-antikoerper-praeparat.
LV10202A (lv) Cilveka karcinomas asociets antigens un to saistosa antiviela

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8601644-1

Effective date: 19911108

Format of ref document f/p: F